The Experimental and Developmental Therapeutics (EDT) program of the Cancer Therapy and Research Center (CTRC) at the University of Texas Health Science Center at San Antonio (UTHSCSA) is focused on improving the therapy of cancer through innovative pre-clinical and clinical research. The activities within this program span the range of experimental and developmental therapeutics from initial target discovery to regulatory approval for new treatments. This program identifies new therapeutic targets for cancer, new therapies and approaches directed at these targets, and has the expertise to help translate discoveries. The EDT program facilitates the assessment of novel therapies by fostering collaboration between pre-clinical and clinical researchers ultimately to provide patients with the best possible treatments. Key themes within EDT include: 1) identification of novel therapeutic targets, 2) synthesis and pre-clinical assessment of new compounds directed at specific targets and 3) preclinical assessment of compounds in novel cancer situations. The integration in December 2007 of UTHSCSA's cancer-focused resources with those of the CTRC's Institute for Drug Development (IDD) has allowed a greater emphasis on the efficient translation of preclinical research into eariy phase clinical studies within the EDT program and will allow rapid further Phase 11/111 exploration of promising approaches. The EDT program has 31 scientific members representing 8 departments from the School of Medicine, the Graduate School of Biomedical Sciences, and important components of the CTRC at UTHSCSA including the IDD and the Greehey Children's Cancer Research Institute. EDT program members currently receive $5.55 million (direct costs) annually in peer-reviewed grants from the NCI, NIH, FDA, and Department of Defense. Training is a very important component of the EDT program's activities. Program members train fellows and graduate students in pre-clinical and clinical departments. The IDD's Advanced Oncology/Hematology Drug Development Fellowship is a unique training program for physicians that focuses specifically on the multidisciplinary nature of anti-cancer therapy development. In summary, the EDT program is a highly integrated multidisciplinary collaborative effort between pre-clinical and clinical scientists, all focused on providing newer, better-targeted and more effective treatments for patients with cancer

Public Health Relevance

The Experimental and Developmental Therapeutics (EDT) Program is the keystone of the CTRC at UTHSCSA's effort to develop and test new treatments for cancer. It is a highly integrated multidisciplinary collaborative effort between diverse disciplines of pre-clinical and clinical scientists, all of whom are focused on improving the prognosis of patients with cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Texas Health Science Center San Antonio
San Antonio
United States
Zip Code
Meng, Jia; Lu, Zhiliang; Liu, Hui et al. (2014) A protocol for RNA methylation differential analysis with MeRIP-Seq data and exomePeak R/Bioconductor package. Methods 69:274-81
Ghosh, Sagar; Hughes, Daniel; Parma, Dorothy Long et al. (2014) Association of obesity and circulating adipose stromal cells among breast cancer survivors. Mol Biol Rep 41:2907-16
Fok, Wilson C; Livi, Carolina; Bokov, Alex et al. (2014) Short-term rapamycin treatment in mice has few effects on the transcriptome of white adipose tissue compared to dietary restriction. Mech Ageing Dev 140:23-9
Gong, Jingjing; Muñoz, Amanda R; Chan, Daniel et al. (2014) STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth. Oncotarget 5:2529-41
Mousavi, Seyed Mohsen; Sundquist, Jan; Hemminki, Kari (2014) Risk of Kaposi sarcoma among immigrants to Sweden. Acta Derm Venereol 94:476-7
Morales, Liza D; Casillas Pavón, Edgar A; Shin, Jun Wan et al. (2014) Protein tyrosine phosphatases PTP-1B, SHP-2, and PTEN facilitate Rb/E2F-associated apoptotic signaling. PLoS One 9:e97104
Biswas, Tanuka; Gu, Xiang; Yang, Junhua et al. (2014) Attenuation of TGF-* signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett 346:129-38
Ankerst, Donna P; Boeck, Andreas; Freedland, Stephen J et al. (2014) Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. World J Urol 32:185-91
Bansal, H; Yihua, Q; Iyer, S P et al. (2014) WTAP is a novel oncogenic protein in acute myeloid leukemia. Leukemia 28:1171-4
Ramirez, Amelie G; Munoz, Edgar; Holden, Alan E C et al. (2014) Incidence of hepatocellular carcinoma in Texas Latinos, 1995-2010: an update. PLoS One 9:e99365

Showing the most recent 10 out of 616 publications